Pain Management Drugs Market : To Rise $91.64 Billion by 2027 | Sector to Grow at a CAGR of 3.8%

September 07, 2023 02:13 PM AEST | By EIN Presswire
 Pain Management Drugs Market : To Rise $91.64 Billion by 2027 | Sector to Grow at a CAGR of 3.8%
Image source: EIN Presswire

Pain management drug market provides an in-depth analysis along with the current trends and future estimations.

PORTLAND, OREGON, UNITED STATES, September 7, 2023/EINPresswire.com/ -- Pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 million by 2027, registering a CAGR of 3.8% from 2020 to 2027. Pain is a complex medical condition, which not only affects physical but also mental well-being of an individual. It is caused due to trauma or tissue damage, and its intensity varies from person to person. Pain control medications help to alleviate pain through various pathways in patient's body. There are various types of medicines available in the pain management drugs market targeting specific biomolecules in the body and manipulating specific mechanisms to avoid pain sensation. On the basis of cause of pain, the treatment provided can be simple or complex. Pain can be managed using a variety of pharmacological and non-pharmacological therapies.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
JOHNSON & JOHNSON, MERCK & CO., INC., ABBOTT LABORATORIES, ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.), MYLAN N.V., ELI LILY AND COMPANY, NOVARTIS INTERNATIONAL AG, GLAXOSMITHKLINE PLC (GSK), PURDUE PHARMA L.P., PFIZER INC.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/404

The opioids segment was the largest contributor to the market growth in 2019, opioids segment is the largest contributor toward the market growth, owing to high popularity of these drugs worldwide. However, the anesthetics segment is anticipated to be the fastest growing segment in the market, owing to frequent use of this drug type during surgeries and rise in number of surgeries globally.

Neuropathic Pain segment accounted for a majority of the pain management drugs market share in 2019 and is expected to exhibit a prominent growth rate during the forecast period, increase in presence of large patient population is the major factor that increases the demand for drugs for neuropathic pain. Cancer pain and chronic back pain were segment is expected to grow at the highest rate throughout the forecast period in 2019, owing to increase in number of surgeries globally and rise in prevalence of chronic diseases that lead to back pain.

On the basis of pain type, the chronic pain segment was the largest contributor to the market growth in 2019, and is expected to grow at a CAGR of 3.9% during the forecast period.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/404

As per the industry experts, long term effect of COVID-19 outbreak is expected to be witnessed over the coming years. This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak will impact the pain management drugs market in the initial phase of the forecast period. The COVID-19 pandemic has stressed healthcare systems worldwide, so that many clinics, pain services are no longer open for public services because of safety. Moreover, throughout the latter half of the forecast period, the demand for pain management drugs is expected to rise. Owing to the factors such as telemedicine, physicians are able to provide guidance to patients for physical exercises at-home for pain relief. This is anticipated to increase the market growth in near future.

𝐕𝐀𝐋𝐔𝐄 𝐏𝐑𝐎𝐏𝐎𝐒𝐈𝐓𝐈𝐎𝐍𝐒 𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐓𝐎 𝐓𝐇𝐄 𝐑𝐄𝐏𝐎𝐑𝐓:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

Comprehensive quantitative and qualitative insights at segment and sub-segment level

Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Winning imperatives

Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

𝐀𝐕𝐄𝐍𝐔𝐄- 𝐀 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐁𝐚𝐬𝐞𝐝 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 (𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐨𝐧-𝐝𝐞𝐦𝐚𝐧𝐝, 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐢𝐜𝐢𝐧𝐠 𝐦𝐨𝐝𝐞𝐥) 𝐎𝐟𝐟𝐞𝐫𝐞𝐝 𝐛𝐲 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

𝐆𝐞𝐭 𝐚𝐧 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐥𝐢𝐛𝐫𝐚𝐫𝐲 𝐨𝐟 𝐫𝐞𝐩𝐨𝐫𝐭𝐬 𝐚𝐭 𝐚𝐧𝐲 𝐭𝐢𝐦𝐞 𝐟𝐫𝐨𝐦 𝐚𝐧𝐲 𝐝𝐞𝐯𝐢𝐜𝐞 𝐚𝐧𝐝 𝐚𝐧𝐲𝐰𝐡𝐞𝐫𝐞. 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬, 𝐟𝐨𝐥𝐥𝐨𝐰 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤: https://www.alliedmarketresearch.com/library-access

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.